The four stages that participants were allocated into were defined as stage 0 (no abnormality), stage 1 (reduced amyloid-β1-42), stage 2 (elevated total-tau and reduced amyloid-β1-42), and “suspected non-AD pathology” [92]. This evidence concerns the gene MAPT and Alzheimer disease.